Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

Trial Details

NCT ID
NCT06899126
Phase
PHASE3
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Trastuzumab Deruxtecan
  • pembrolizumab
  • Pemetrexed
  • Chemotherapy
Locations (sample)
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Fountain Valley, California, United States|33.70918,-117.95367
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Santa Rosa, California, United States|38.44047,-122.71443

Key Eligibility Criteria

  • Sign and date the Tissue Screening ICF, prior to any Tissue Screening procedure. Sign and date the Main ICF, prior to the start of any trial-specif…
  • Sign and date the Optional PGx ICF (included in the Main Screening ICF) prior to any PGx procedure, and the Pregnant Partner ICF, if applicable.
  • Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is …
  • Histologically documented non-squamous locally advanced unresectable or metastatic

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →